Safety assessments indicated that gastrointestinal adverse situations, principally nausea and diarrhea, ended up dose-dependent but typically moderate and transient. These results founded the therapeutic window and knowledgeable dose selection for subsequent Period 3 trials.Continued refinement of formulation and dosing strategies may perhaps furth